HAEMONETICS CORP/MASS (HAE) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:HAE - US4050241003 - Common Stock
HAE Key Statistics, Chart & Performance
The current stock price of HAE is 84.04 USD. In the past month the price increased by 0.24%. In the past year, price increased by 9.61%.
HAE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 20.13 | 16.53B | ||
| SOLV | SOLVENTUM CORP | 14.44 | 14.88B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.64 | 12.24B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 25.05 | 5.52B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.38 | 4.50B | ||
| ICUI | ICU MEDICAL INC | 19.05 | 3.74B | ||
| XRAY | DENTSPLY SIRONA INC | 7.9 | 2.49B | ||
| UFPT | UFP TECHNOLOGIES INC | 29.6 | 1.97B | ||
| NEOG | NEOGEN CORP | 32.37 | 2.11B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.12B | ||
| EMBC | EMBECTA CORP | 4.3 | 746.59M | ||
| BVS | BIOVENTUS INC - A | 13.56 | 662.08M |
Related stock screener links
About HAE
Company Profile
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. The firm is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
Company Info
HAEMONETICS CORP/MASS
125 Summer Street
Boston MASSACHUSETTS 02110 US
CEO: Christopher A. Simon
Employees: 3657
Phone: 17818487100
HAEMONETICS CORP/MASS / HAE FAQ
What does HAEMONETICS CORP/MASS do?
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. The firm is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
Can you provide the latest stock price for HAEMONETICS CORP/MASS?
The current stock price of HAE is 84.04 USD. The price increased by 1.25% in the last trading session.
Does HAE stock pay dividends?
HAE does not pay a dividend.
What is the ChartMill technical and fundamental rating of HAE stock?
HAE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the valuation of HAEMONETICS CORP/MASS (HAE) based on its PE ratio?
The PE ratio for HAEMONETICS CORP/MASS (HAE) is 17.51. This is based on the reported non-GAAP earnings per share of 4.8 and the current share price of 84.04 USD.
How many employees does HAEMONETICS CORP/MASS have?
HAEMONETICS CORP/MASS (HAE) currently has 3657 employees.
What is the next earnings date for HAE stock?
HAEMONETICS CORP/MASS (HAE) will report earnings on 2026-02-04, before the market open.
HAE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to HAE. When comparing the yearly performance of all stocks, HAE is one of the better performing stocks in the market, outperforming 90.7% of all stocks.
HAE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to HAE. While HAE has a great profitability rating, there are some minor concerns on its financial health.
HAE Financial Highlights
Over the last trailing twelve months HAE reported a non-GAAP Earnings per Share(EPS) of 4.8. The EPS increased by 17.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.67% | ||
| ROA | 6.89% | ||
| ROE | 19.81% | ||
| Debt/Equity | 1.08 |
HAE Forecast & Estimates
15 analysts have analysed HAE and the average price target is 93.53 USD. This implies a price increase of 11.3% is expected in the next year compared to the current price of 84.04.
For the next year, analysts expect an EPS growth of 8.59% and a revenue growth -3.06% for HAE